ClinVar Miner

Submissions for variant NM_000257.4(MYH7):c.2221G>T (p.Gly741Trp)

dbSNP: rs121913632
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Cardiomyopathy Variant Curation Expert Panel RCV000678722 SCV000564428 pathogenic Hypertrophic cardiomyopathy 2016-12-15 reviewed by expert panel curation The c.2221G>T (p.Gly741Trp) variant in MYH7 has been reported in >15 individuals with hypertrophic cardiomyopathy (PS4; PMID: 8533830; PMID:15856146; PMID:27532257; Partners LMM ClinVar SCV000203910.4; AGCMC Sydney ClinVar SCV000212638.1). This variant segregated with disease in 5 affected individuals (PP1_Moderate; PMID:15856146; AGCMC Sydney ClinVar SCV000212638.1). This variant was absent from large population studies (PM2; This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2221G>C p.Gly741Arg - Variation ID 14098). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS4; PM1; PM2; PM5; PP1_Moderate; PP3
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000678722 SCV000203910 likely pathogenic Hypertrophic cardiomyopathy 2014-04-17 criteria provided, single submitter clinical testing The Gly741Trp variant in MYH7 has been reported in at least 3 individuals with H CM (Arai 1995, Perrot 2005, Pan 2012) and segregated with disease in 4 affected relatives from 2 families. This variant has also been previously identified by o ur laboratory in 5 individuals with HCM. It was absent from large population stu dies. Glycine (Gly) at position 741 is conserved in mammals, though not across evolutionarily distant species (birds and fish). The change to tryptophan (Trp) was predicted to be pathogenic using a computational tool clinically validated b y our laboratory. This tool's pathogenic prediction is estimated to be correct 9 4% of the time (Jordan 2011). In addition, another variant at this position (Gly 741Arg) is reported to be disease-causing. In summary, although additional studi es are required to fully establish its clinical significance, the Gly741Trp vari ant is likely pathogenic.
GeneDx RCV000158523 SCV000208458 pathogenic not provided 2021-08-13 criteria provided, single submitter clinical testing Identified in a multiple patients with HCM referred for genetic testing at GeneDx and in published literature (Arai et al., 1995; Perrot et al., 2005; Pan et al., 2012; Zou et al., 2013; Kapplinger et al., 2014; Walsh et al., 2017; Bagnall et al., 2018); Reported in ClinVar as pathogenic by the ClinGen Inherited Cardiomyopathy Expert Panel (SCV000564428.2; Landrum et al., 2016); Not observed at significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31006259, 29907873, 29300372, 27532257, 32344918, 31737537, 29369293, 28166811, 30025578, 28606303, 24810389, 24510615, 23283745, 15856146, 23074333, 21310275, 27247418, 25935763, 26914223, 8533830)
Agnes Ginges Centre for Molecular Cardiology, Centenary Institute RCV000678722 SCV000212638 pathogenic Hypertrophic cardiomyopathy 2018-11-02 criteria provided, single submitter research This MYH7 Gly741Trp variant has been reported in mutliple HCM cases (Arai S, et al., 1995; Perrot A, et al., 2005; Otsuka H, et al., 2012; Santos S, et al., 2012; Pan S, et al., 2012; Kapplinger JD, et al., 2014; Walsh R, et al., 2017), and the variant was shown to segregate with disease in affected family members (Arai S, et al., 1995; Perrot A, et al., 2005). Interestingly, a variant at the same position resulting in a different amino acid change, Gly741Arg, has extensively reported in HCM cases (Fananapazir L, et al., 1993; Richard P, et al., 2003; Van Driest SL, et al., 2004; Song L, et al., 2005; Kaski JP, et al., 2009; Marsiglia JD, et al., 2013; Kapplinger JD, et al., 2014; Walsh R, et al., 2017). The MYH7 Gly741Trp variant is absent in the Exome Aggregation Consortium dataset (, and the 1000 genomes project ( We have identified this variant in 5 HCM Probands. All four probands have a family history of disease, but segregation was only possible in 3 of these families and we found this variant to segregate in total of 4 affected first degree family members. In silico tools SIFT, PolyPhen2 and MutationTaster predict this variant to be deleterious. In a large HCM population study Walsh et al., showed that MYH7 variants identified in HCM cases were found to cluster between amino acids 181- 937 (2017), this implies that variants in this region are likely to cause a HCM phenotype. Based on the adapted ACMG criteria (Kelly MA, et al., 2018) this variant has been reported in more than 15 unrelated probands (PS4), segregates with disease in multiple families (PP1_strong), is located in a mutational hotspot (PM1), is rare in the general population (PM2), affects the same amino acid as another disease-causing variant (PM5), and is predicted to be deleterious by multiple in silico tools (PP3), therefore we classify MYH7 Gly741Trp as 'Pathogenic'.
Eurofins Ntd Llc (ga) RCV000158523 SCV000226869 pathogenic not provided 2015-01-15 criteria provided, single submitter clinical testing
Ambry Genetics RCV000619837 SCV000739985 pathogenic Cardiovascular phenotype 2021-04-13 criteria provided, single submitter clinical testing The p.G741W pathogenic mutation (also known as c.2221G>T), located in coding exon 18 of the MYH7 gene, results from a G to T substitution at nucleotide position 2221. The glycine at codon 741 is replaced by tryptophan, an amino acid with highly dissimilar properties. This alteration is located in the myosin head domain, which contains a statistically significant clustering of pathogenic missense variants (Homburger JR et al. Proc Natl Acad Sci U S A, 2016 06;113:6701-6; Walsh R et al. Genet Med, 2017 02;19:192-203; Ambry internal data). This variant has been described in several hypertrophic cardiomyopathy (HCM) cohorts and has been observed to co-segregate with disease in families (Arai S et al. Am J Med Genet. 1995;58:267-76; Perrot A et al. J Mol Med. 2005;83:468-77; Bagnall RD et al. J Am Coll Cardiol, 2018 07;72:419-429; Walsh R et al. Genet Med, 2017 02;19:192-203). In addition, another substitution at the same codon, p.G741R (c.2221G>A and c.2221G>C), has been described in multiple individuals with HCM (Fananapazir L et al. Proc Natl Acad Sci U.S.A. 1993;90(9):3993-7). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000678722 SCV000813145 pathogenic Hypertrophic cardiomyopathy 2024-01-20 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with tryptophan, which is neutral and slightly polar, at codon 741 of the MYH7 protein (p.Gly741Trp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with hypertrophic cardiomyopathy (HCM) (PMID: 8533830, 15856146, 22112859, 22429680, 25935763, 26914223, 27532257). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 177665). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYH7 protein function with a positive predictive value of 95%. This variant is found within a region of MYH7 between codons 181 and 937 that contains the majority of the myosin head domain. Missense variants in this region have been shown to be significantly overrepresented in individuals with hypertrophic cardiomyopathy (PMID: 27532257). For these reasons, this variant has been classified as Pathogenic.
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute RCV000158523 SCV001433190 pathogenic not provided 2020-01-07 criteria provided, single submitter clinical testing
Genetics and Molecular Pathology, SA Pathology RCV002466449 SCV002761790 pathogenic Hypertrophic cardiomyopathy 1 2021-03-22 criteria provided, single submitter clinical testing
Stanford Center for Inherited Cardiovascular Disease, Stanford University RCV000158523 SCV000280319 likely pathogenic not provided 2015-09-09 no assertion criteria provided clinical testing Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. MYH7 p.Gly741Trp (c.2221G>T) The variant has been seen in at least 9 unrelated individuals with HCM with moderately segregation data in one family. Arai et al (1995) reported a Japanese family with four individuals who all had HCM and carried p.Gly741Trp. The authors of that paper refer to an additional Japanese case, reported in a book chapter by Kimura et al (1994). Perrot et al (2005) reported two siblings from a German family who both had HCM and this variant. Santos et al (2012) observed the variant in one of 80 Portuguese patients with HCM. Ackerman's group observed the variant in 4 patients in their cohort of 1053 unrelated patients with HCM who underwent DHLPC-based analysis of 9 sarcomere genes at Mayo (Bos et al 2014). It is not currently listed in ClinVar (as of October 3rd 2014). In silico analysis with PolyPhen-2 predicts the variant to be probably damaging and mutationtaster predicts it to be disease causing. The glycine at codon 741 is conserved across species, as are neighboring amino acids. Two other variants at the same codon have been associated with cardiomyopathy: p.Gly741Arg (Van Driest et al 2004, we consider this variant very likely disease causing), p.Gly741Ala (primary data unavailable). Variants at nearby codons have also been reported in association with cardiomyopathy (p.Ile736Val, p.Ile736Thr, p.Ile736Met, p.Ala742Glu, p.Glu743Asp). Functional studies have shown that another variant at this codon, p.Gly741Arg, confers reduced isometric force generation and decreased velocity of shortening (Lankford et al 1995). In total the variant has not been seen in ~6896 published controls and publicly available population datasets. There is no variation at codon 741 listed in the NHLBI Exome Sequencing Project dataset, which currently includes variant calls on ~6500 Caucasian and African American individuals (as of 1 Oct 2014). The variant is listed in dbSNP (rs121913632), however the only submissions are OMIM and LMM (as of 1 October 2014). The variant is not listed in the 1000 genomes dataset (as of 1 October 2014). The variant was not observed in the following published control samples: 96 (Perrot et al 2005), 100 (Santos et al 2012), 200 (Bos et al 2014).
Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital RCV000678722 SCV000804893 likely pathogenic Hypertrophic cardiomyopathy 2016-03-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.